Sanctuary Advisors LLC Sells 2,909 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Sanctuary Advisors LLC reduced its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 5.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 50,681 shares of the company’s stock after selling 2,909 shares during the quarter. Sanctuary Advisors LLC’s holdings in Intellia Therapeutics were worth $591,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of NTLA. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after purchasing an additional 794 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in Intellia Therapeutics by 71.0% in the third quarter. Harbor Capital Advisors Inc. now owns 79,205 shares of the company’s stock valued at $1,628,000 after buying an additional 32,893 shares during the period. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after acquiring an additional 659,651 shares during the last quarter. Lewis Asset Management LLC grew its holdings in Intellia Therapeutics by 42.5% during the 3rd quarter. Lewis Asset Management LLC now owns 66,308 shares of the company’s stock worth $1,363,000 after acquiring an additional 19,775 shares during the period. Finally, Atria Investments Inc raised its position in shares of Intellia Therapeutics by 24.3% in the 3rd quarter. Atria Investments Inc now owns 23,099 shares of the company’s stock worth $475,000 after acquiring an additional 4,511 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 29,000 shares of company stock valued at $352,551 in the last three months. 3.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on NTLA shares. Wells Fargo & Company lowered their target price on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Friday. Barclays lowered their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday. Canaccord Genuity Group restated a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a report on Tuesday, November 19th. The Goldman Sachs Group reiterated a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday. Finally, Chardan Capital reduced their target price on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $42.12.

Intellia Therapeutics Trading Down 7.1 %

Shares of Intellia Therapeutics stock opened at $10.09 on Friday. The company has a market capitalization of $1.03 billion, a P/E ratio of -1.85 and a beta of 1.80. The stock has a fifty day simple moving average of $10.85 and a 200 day simple moving average of $15.64. Intellia Therapeutics, Inc. has a 12-month low of $8.96 and a 12-month high of $34.87.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.